期刊文献+

绝经后女性冠心病患者雌激素、C反应蛋白与白介素6水平变化及其关系 被引量:3

Levels of plasma estrogen,C-reactive protein and interleukin-6 in postmenopausal female patients with coronary heart disease and their mutual relationship
暂未订购
导出
摘要 目的探讨绝经后女性冠心病患者体内雌激素、C反应蛋白与白介素6水平的变化以及雌激素与C反应蛋白、白介素6的关系。方法对31例符合要求的绝经后女性冠心病患者与44例非冠心病患者股动脉采血检测雌二醇、C反应蛋白与白介素6的浓度。结果冠心病组的雌激素水平明显低于非冠心病组(18±7)vs(24±10)ng/L,P<0.05,而C反应蛋白与白介素6水平则明显高于非冠心病组(6.9±5.9)vs(1.9±1.3)mg/L;(59±11)vs(46±13)ng/L,P<0.01。雌二醇与C反应蛋白、白介素6没有明显的相关性(r=-0.106,-0.203,P>0.05)。结论雌二醇、C反应蛋白和白介素6在绝经后女性冠心病的发病中起着重要的作用。雌激素影响女性冠心病的发病与C反应蛋白以及白介素6没有明显的相关性。 Objective To investigate the levels of plasma estrogen,C-reactive protein (CRP) and interleukin (IL)-6 in postmenopausal female patients with coronary heart disease (CHD) and the association of estrogen level with CRP and IL-6 levels.Methods The plasma levels of estrogen,CRP and IL-6 were measured in 31 postmeno-pausal females with CHD and 44 ones without CHD.Results Plasma level of estrogen was obviously lower (18±7)vs (24±10)ng/L,P0.05,while levels of CRP and IL-6 were obviously higher (6.9±5.9)vs (1.9±1.3)mg/L;(59±11) vs (46±13) ng/L,P0.01 in CHD patients than in non-CHD ones.The plasma level of estrogen had no association with that of CRP and IL-6 (r=-0.106,-0.203,P0.05 ).Conclusion Estrogen,CRP and IL-6 play important roles in the pathogenesis of CHD in postmenopausal female patients.The effect of estrogen on the pathogenesis of CHD in female patients has no association with CRP and IL-6.
出处 《中华老年多器官疾病杂志》 2010年第6期522-524,共3页 Chinese Journal of Multiple Organ Diseases in the Elderly
关键词 绝经 冠心病 雌激素 C反应蛋白 白介素6 menopause coronary heart disease estrogen C-reactive protein interleukin-6
  • 相关文献

参考文献11

  • 1Pilz H. vascular (HRT) (17-18) Primary and secondary prevention of cardioevents through hormone replacement therapy [J].Wien Med Wochenschr, 2005, 155 397-403.
  • 2Meng CQ. Atherosclerosis is an inflammatory disorder after all [J]. Curr Top Med Chem, 2006, 6 (2): 93-102.
  • 3Gensini GG. A more meaningful scoring system for determining the severity of coronary heart disease[J]. Am J Cardiol, 1983, 51(3) : 606-612.
  • 4Morise AP. Assessment of estrogen status as a marker of prognosis in women with symptoms of suspected coronary artery disease presenting for stress testing [J].Am J Cardiol, 2006, 97(3): 367-374.
  • 5Grodstein F, Manson JE, Stampfer MJ. Hormone therapy and coronary heart disease: the role of time since menopause and age at hormone initiation [J]. Womens Health (Larchmt), 2006, 15(1) : 35-44.
  • 6Pradham AD, Manson JE, Rossouw J, et al. Inflammatory biomarkers, hormone replacement therapy, and incident coronary heart disease: prospective analysis from the Women's Health Initiative Observational Study[J]. JAMA, 2002, 288(8):980-987.
  • 7Ridker PM, Morrow DA. C reaction protein and cardiovascular risk rational for screening and primary prevention[J]. Am J Cordiol, 2003, 21(3):315-325.
  • 8Humphries SE, Luong LA, Ogg MS, et al. The interleukin-6 -174 G/C promoter polymorphism is associated with risk of coronary heart disease and systolic blood pressure in healthy men[J]. Eur Heart J, 2001, 22(24) : 2243-2252.
  • 9Sesmilo G, Miller KK, Hayden D, et al. Inflammatory cardiovascular risk markers in women with hypo- pituitarism[J]. Clin Endocrinol Metab, 2001, 86 (12): 5774-5781.
  • 10Tiidus PM. Estrogen and sex influence on muscle damage and inflammation: evidence from animal models[J].Cur Opin Clin Nutr Metab Care, 2001, 4 (6) : 509-513.

同被引文献15

引证文献3

二级引证文献13

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部